Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26557808
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Galectin-9 is Involved in Immunosuppression Mediated by Human Bone Marrow-derived
Clonal Mesenchymal Stem Cells
#MMPMID26557808
Kim SN
; Lee HJ
; Jeon MS
; Yi T
; Song SU
Immune Netw
2015[Oct]; 15
(5
): 241-51
PMID26557808
show ga
Bone marrow-derived mesenchymal stem cells (MSCs) have immunomodulatory
properties and can suppress exaggerated pro-inflammatory immune responses.
Although the exact mechanisms remain unclear, a variety of soluble factors are
known to contribute to MSC-mediated immunosuppression. However, functional
redundancy in the immunosuppressive properties of MSCs indicates that other
uncharacterized factors could be involved. Galectin-9, a member of the
?-galactoside binding galectin family, has emerged as an important regulator of
innate and adaptive immunity. We examined whether galectin-9 contributes to
MSC-mediated immunosuppression. Galectin-9 was strongly induced and secreted from
human MSCs upon stimulation with pro-inflammatory cytokines. An in vitro
immunosuppression assay using a knockdown approach revealed that
galectin-9-deficient MSCs do not exert immunosuppressive activity. We also
provided evidence that galectin-9 may contribute to MSC-mediated
immunosuppression by binding to its receptor, TIM-3, expressed on activated
lymphocytes, leading to apoptotic cell death of activated lymphocytes. Taken
together, our findings demonstrate that galectin-9 is involved in MSC-mediated
immunosuppression and represents a potential therapeutic factor for the treatment
of inflammatory diseases.
free
free
free
